Literature DB >> 19897076

Molecular bases of methamphetamine-induced neurodegeneration.

Jean Lud Cadet1, Irina N Krasnova.   

Abstract

Methamphetamine (METH) is a highly addictive psychostimulant drug, whose abuse has reached epidemic proportions worldwide. The addiction to METH is a major public concern because its chronic abuse is associated with serious health complications including deficits in attention, memory, and executive functions in humans. These neuropsychiatric complications might, in part, be related to drug-induced neurotoxic effects, which include damage to dopaminergic and serotonergic terminals, neuronal apoptosis, as well as activated astroglial and microglial cells in the brain. Thus, the purpose of the present paper is to review cellular and molecular mechanisms that might be responsible for METH neurotoxicity. These include oxidative stress, activation of transcription factors, DNA damage, excitotoxicity, blood-brain barrier breakdown, microglial activation, and various apoptotic pathways. Several approaches that allow protection against METH-induced neurotoxic effects are also discussed. Better understanding of the cellular and molecular mechanisms involved in METH toxicity should help to generate modern therapeutic approaches to prevent or attenuate the long-term consequences of psychostimulant use disorders in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19897076      PMCID: PMC8247532          DOI: 10.1016/S0074-7742(09)88005-7

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  145 in total

1.  Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity.

Authors:  X Deng; B Ladenheim; L I Tsao; J L Cadet
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

2.  High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus.

Authors:  John F Bowyer; Syed Ali
Journal:  Synapse       Date:  2006-12-01       Impact factor: 2.562

3.  Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage.

Authors:  Donald M Kuhn; Dina M Francescutti-Verbeem; David M Thomas
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

4.  Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure.

Authors:  Raul Gonzalez; Julie D Rippeth; Catherine L Carey; Robert K Heaton; David J Moore; Brian C Schweinsburg; Mariana Cherner; Igor Grant
Journal:  Drug Alcohol Depend       Date:  2004-11-11       Impact factor: 4.492

5.  Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol.

Authors:  Myreille D'Astous; Tapasdip M Gajjar; Dean E Dluzen; Thérèse Di Paolo
Journal:  Neuroendocrinology       Date:  2004-07-09       Impact factor: 4.914

6.  The effect of relapse on cognition in abstinent methamphetamine abusers.

Authors:  Sara L Simon; Jennifer Dacey; Susan Glynn; Richard Rawson; Walter Ling
Journal:  J Subst Abuse Treat       Date:  2004-07

7.  Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine.

Authors:  J F Nash; H Y Meltzer; G A Gudelsky
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

8.  Effects of 7-nitroindazole, an NOS inhibitor on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in mice.

Authors:  S F Ali; Y Itzhak
Journal:  Ann N Y Acad Sci       Date:  1998-05-30       Impact factor: 5.691

9.  Why is parkinsonism not a feature of human methamphetamine users?

Authors:  Anna Moszczynska; Paul Fitzmaurice; Lee Ang; Kathryn S Kalasinsky; Gregory A Schmunk; Frank J Peretti; Sally S Aiken; Dennis J Wickham; Stephen J Kish
Journal:  Brain       Date:  2003-11-25       Impact factor: 13.501

10.  Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation.

Authors:  David M Thomas; Paul D Walker; Joyce A Benjamins; Timothy J Geddes; Donald M Kuhn
Journal:  J Pharmacol Exp Ther       Date:  2004-05-26       Impact factor: 4.030

View more
  79 in total

1.  Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.

Authors:  Lisa M McFadden; Madison M Hunt; Paula L Vieira-Brock; Janice Muehle; Shannon M Nielsen; Scott C Allen; Glen R Hanson; Annette E Fleckenstein
Journal:  Drug Alcohol Depend       Date:  2012-05-28       Impact factor: 4.492

2.  A stress steroid triggers anxiety via increased expression of α4βδ GABAA receptors in methamphetamine dependence.

Authors:  H Shen; A Mohammad; J Ramroop; S S Smith
Journal:  Neuroscience       Date:  2013-08-29       Impact factor: 3.590

3.  Gender differences in the effect of tobacco use on brain phosphocreatine levels in methamphetamine-dependent subjects.

Authors:  Young-Hoon Sung; Deborah A Yurgelun-Todd; Douglas G Kondo; Xian-Feng Shi; Kelly J Lundberg; Tracy L Hellem; Rebekah S Huber; Erin C McGlade; Eun-Kee Jeong; Perry F Renshaw
Journal:  Am J Drug Alcohol Abuse       Date:  2015-04-14       Impact factor: 3.829

Review 4.  Effects of prenatal methamphetamine exposure: a review of cognitive and neuroimaging studies.

Authors:  Maja A Kwiatkowski; Annerine Roos; Dan J Stein; Kevin G F Thomas; Kirsty Donald
Journal:  Metab Brain Dis       Date:  2013-12-28       Impact factor: 3.584

5.  Repeated co-administrations of alcohol- and methamphetamine-produced anxiogenic effect could be associated with the neurotoxicity in the dentate gyrus.

Authors:  Jia-Ying Chuang; Wan-Ting Chang; Chianfang G Cherng; Gour-Shenq Kao; Lung Yu
Journal:  J Neural Transm (Vienna)       Date:  2011-04-17       Impact factor: 3.575

6.  Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Derong Ding; Justin R Nickell; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2015-05-09       Impact factor: 2.823

7.  Distinct roles of dopamine D3 receptors in modulating methamphetamine-induced behavioral sensitization and ultrastructural plasticity in the shell of the nucleus accumbens.

Authors:  Jie Zhu; Yanjiong Chen; Na Zhao; Guofen Cao; Yonghui Dang; Wei Han; Ming Xu; Teng Chen
Journal:  J Neurosci Res       Date:  2012-04       Impact factor: 4.164

8.  Gray-matter volume in methamphetamine dependence: cigarette smoking and changes with abstinence from methamphetamine.

Authors:  Angelica M Morales; Buyean Lee; Gerhard Hellemann; Joseph O'Neill; Edythe D London
Journal:  Drug Alcohol Depend       Date:  2012-03-22       Impact factor: 4.492

9.  Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; Elena Shumay; Frank Telang; Peter K Thanos; David Alexoff
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

10.  The danger-associated molecular pattern HMGB1 mediates the neuroinflammatory effects of methamphetamine.

Authors:  Matthew G Frank; Sweta Adhikary; Julia L Sobesky; Michael D Weber; Linda R Watkins; Steven F Maier
Journal:  Brain Behav Immun       Date:  2015-08-04       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.